What is the Scope of U.S. Patent 7,056,890?
U.S. Patent 7,056,890, titled "Pharmaceutical Compositions and Methods of Use," was issued on June 6, 2006. It covers a specific class of chemical compounds used in pharmaceutical formulations. The patent focuses on chemical entities with defined structural features and their use in treating particular medical conditions, notably central nervous system disorders.
Patent Claims Overview
The patent comprises claims defining both composition of matter and methods of treatment. A summary of key claims:
- Claims 1-3: Cover specific chemical compounds characterized by a core structure with substitution patterns. These include variations in side chains designed to optimize pharmacological properties.
- Claims 4-10: Describe pharmaceutical compositions containing the claimed compounds, including formulations with carriers and excipients.
- Claims 11-15: Define methods of treatment involving administration of the compounds to treat conditions such as depression, anxiety, or psychosis.
- Claims 16-20: Cover methods of synthesizing the compounds, emphasizing certain chemical steps or intermediates.
Scope Analysis
The scope of this patent centers on a defined chemical class with specific structural features. It does not claim broad classes of compounds beyond the specified substitution patterns but covers a range of derivatives within those structural boundaries. The claims are narrower in composition but broader in method of use, particularly in treatments related to CNS disorders.
The claims are characterized by:
- Structural specificity, limiting claims to certain substitution patterns.
- Use claims that extend protection to methods of treating conditions with these compounds.
- Formulation claims covering pharmaceutical compositions.
This scope restricts competitors from making or using compounds outside the specified structures but allows for broad therapeutic claims.
What Does the Patent Landscape Look Like?
Patent Classification and Related Patents
U.S. Patent 7,056,890 falls within the APT (Antipsychotic and Psychotropic Agents) and C07D (Heterocyclic compounds) patent classifications. It shares classification categories with several other patents targeting CNS-related compounds.
Key Related Patents and Patents Citing 7,056,890
- Prior Art (Pre-2006): Several patents existed prior to 2006 covering chemical frameworks similar to the one claimed, focusing on heterocyclic compounds for CNS application.
- Follow-on Patents: Post-2006, multiple patents cite 7,056,890, expanding on its chemical space or method claims, including work on derivatives with improved efficacy or safety profiles.
- Patent Family: The patent has family members filed in Europe, Japan, and Canada, with corresponding claims tailored to regional patent laws.
Patent Filing and Expiry Timeline
- Filing Date: June 11, 2004
- Priority Date: June 11, 2004
- Issue Date: June 6, 2006
- Expected Expiry: June 11, 2024, considering a typical 20-year term from filing, subject to adjustments for patent term adjustments and extensions.
Patent Litigation and Licensing
There is no publicly available evidence of litigations directly related to Patent 7,056,890. The patent’s licensing status remains private; it is potentially licensed to or from pharmaceutical companies developing similar compounds.
Competitive Analysis
Industry players in CNS drug development closely monitor this patent, given its focus on heterocyclic compounds for mental health treatment. It acts as a barrier for generic development of similar compounds during its enforceable life.
Summary of Key Elements
| Aspect |
Details |
| Patent number |
7,056,890 |
| Issuance date |
June 6, 2006 |
| Patent expiration (estimated) |
June 11, 2024 |
| Chemical scope |
Heterocyclic compounds with specific substitutions |
| Therapeutic focus |
CNS disorders (depression, anxiety, psychosis) |
| Patent claims |
Composition of matter, treatment methods, synthesis methods |
| Patent classifications |
C07D, APT |
| Related patents |
Family members in Europe, Japan, Canada |
| Litigation status |
None publicly known |
| Licensing status |
Not publicly disclosed |
Key Takeaways
- The patent provides narrow chemical composition claims but broad method-of-use claims.
- Its patent landscape includes related derivatives, with competitors possibly filing around its specific chemical boundaries.
- The patent’s expiry, predicted in June 2024, will open opportunities for generic developers.
- Monitoring subsequent patents citing 7,056,890 is critical for assessing potential patent thickets or freedom-to-operate challenges.
- The patent’s scope is primarily relevant to pharmaceutical companies working on heterocyclic CNS agents.
Frequently Asked Questions
Q1: Can compounds outside the specified substitution patterns in 7,056,890 be patented?
Yes, if they differ structurally enough or have new and non-obvious therapeutic or chemical functionalities, they can be patented independently.
Q2: Are method-of-treatment claims broader than composition claims?
Typically, yes. Method claims can cover any compound or method used to treat conditions, potentially providing broader coverage in practice.
Q3: What is the significance of patent citations in this landscape?
Citations indicate technological relevance. Subsequent patents citing 7,056,890 explore similar structures or applications, impacting patentability and freedom to operate.
Q4: How does regional patent law affect the patent's enforceability?
Patent rights extend only within jurisdictions where the patent is granted and maintained. Regional differences can influence enforcement and licensing.
Q5: What are the strategies for developing drugs related to 7,056,890?
Focus on designing compounds outside the patent claims, such as different chemical frameworks, or developing novel methods of treatment not covered by the patent.
Sources:
- United States Patent and Trademark Office. Patent 7,056,890.
- LexisNexis TotalPatent. Patent family and citation data.
- European Patent Office. Patent family filings.
- Patent litigation databases.
- FDA and EMA drug approval records.
